Focused On-demand Library for Mitochondrial dicarboxylate carrier

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UBX3

UPID:

DIC_HUMAN

Alternative names:

Solute carrier family 25 member 10

Alternative UPACC:

Q9UBX3; Q542Z3; Q96BA1; Q96IP1

Background:

The Mitochondrial dicarboxylate carrier, also known as Solute carrier family 25 member 10, plays a pivotal role in cellular energy metabolism. It facilitates the exchange of key metabolites across the mitochondrial inner membrane, impacting gluconeogenesis, fatty acid metabolism, urea synthesis, and sulfur metabolism. This protein's activity is crucial in liver function, regulating fatty acid release from adipocytes and influencing systemic insulin sensitivity.

Therapeutic significance:

Linked to Mitochondrial DNA depletion syndrome 19, a severe mitochondrial disorder, understanding the role of the Mitochondrial dicarboxylate carrier could open doors to potential therapeutic strategies. Its involvement in metabolic processes makes it a target for addressing the underlying metabolic dysfunctions in this syndrome.